Head-to-head evidence
tezepelumab vs WIN378
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
tezepelumab · Tezspire
Marketed by AstraZeneca and partners
NCT03347279 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison.
Next expected readout: November 2026 · NCT06705764 (registry estimate)
WIN378
Developed by Windward Bio under a licence from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05790694 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2027 · NCT07120503 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tezepelumab's landscape · WIN378's landscape